TearClear Files Investigational New Drug (IND) Application To Begin Its Clinical Trial for TC-002 Latanoprost Ophthalmic Solution, 0.005%
UF startup and UF Innovate | Sid Martin Biotech company TearClear, a late clinical-stage ophthalmic pharmaceutical company, has filed an Investigational New Drug (IND) application to conduct a registrational study for its lead glaucoma candidate, TC-002 latanoprost ophthalmic solution, 0.005%.
Approximately 30%-40% of patients who rely on preserved, chronic glaucoma therapies show signs of moderate to severe Ocular Surface Disease (OSD)1. Studies have suggested that the removal of preservatives may be beneficial for the ocular health of such patients. To date, options for these patients have been less than adequate.
TearClear is the first and only company to develop products that keep BAK-preserved formulations safely in the bottle and deliver pristine, preservative-free drops of trusted medicines to the eye.
“We are confident that improving the health of the ocular surface matters,” Stuart Raetzman, TearClear’s CEO stated. “Responding to that unmet need has propelled us to this important milestone and it is what drives us to expand our efforts for other glaucoma therapies and to important therapies beyond glaucoma that intersect with OSD.”
Learn more about TearClear Files Investigational New Drug (IND) Application To Begin Its Clinical Trial for TC-002 Latanoprost Ophthalmic Solution, 0.005%.